Abstract
The norepinephrine transporter (NET) is the carrier that drives the neuronal norepinephrine uptake mechanism (uptake1) in mammalian hearts. The radioligand [3H]mazindol binds with high affinity to NET. In this study, the kinetics of [3H]mazindol binding to NET were measured using a rat heart membrane preparation. Results from these studies were used to set up saturation binding assays designed to measure cardiac NET densities (Bmax) and competitive inhibition assays designed to measure inhibitor binding affinities (KI) for NET. Saturation binding assays measured NET densities in rat, rabbit, and canine hearts. Assay reproducibility was assessed and the effect of NaCl concentration on [3H]mazindol binding to NET was studied using membranes from rat and canine hearts. Specificity of [3H]mazindol binding to NET was determined in experiments in which the neurotoxin 6-hydroxydopamine (6-OHDA) was used to selectively destroy cardiac sympathetic nerve terminals in rats. Competitive inhibition studies measured KI values for several NET inhibitors and substrates. In kinetic studies using rat heart membranes, [3H]mazindol exhibited a dissociation rate constant koff=0.0123±0.0007 min−1 and an association rate constant kon=0.0249±0.0019 nM−1min−1. In saturation binding assays, [3H]mazindol binding was monophasic and saturable in all cases. Increasing the concentration of NaCl in the assay buffer increased binding affinity significantly, while only modestly increasing Bmax. Injections of 6-OHDA in rats decreased measured cardiac NET Bmax values in a dose-dependent manner, verifying that [3H]mazindol binds specifically to NET from sympathetic nerve terminals. Competitive inhibition studies provided NET inhibitor and substrate KI values consistent with previously reported values. These studies demonstrate the high selectivity of [3H]mazindol binding for the norepinephrine transporter in membrane preparations from mammalian hearts.
Similar content being viewed by others
References
Armour JA (1998) Myocardial ischaemia and the cardiac nervous system. Cardiovasc Res 41:41–54
Böhm M, La Rosée K, Schwinger RHG, Erdmann E (1995) Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25:145–153
Böhm M, Castellano M, Flesch M, Maack C, Moll M, Paul M, Schiffer F, Zolk O (1998) Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy. Hypertension 32:831–837
Bönisch H, Harder R (1986) Binding of 3H-desipramine to the neuronal noradrenaline carrier of rat phaeochromocytoma cells (PC-12 cells). Naunyn-Schmiedebergs Arch Pharmacol 334:403–411
Chakraborty PK, Gildersleeve DL, Jewett DM, Toorongian SA, Kilbourn MR, Schwaiger M, Wieland DM (1993) High yield synthesis of high specific activity R-(−)-[11C]epinephrine for routine PET studies in humans. Nucl Med Biol 20:939–944
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823
De Champlain J (1971) Degeneration and regrowth of adrenergic nerve fibers in the rat peripheral tissues after 6-hydroxydopamine. Can J Physiol Pharmacol 49:345–355
Del Rosario RB, Jung Y-W, Chakraborty PK, Sherman PS, Wieland DM (1996) Synthesis and preliminary evaluation of [C-11] phenylephrine for mapping heart neuronal function. Nucl Med Biol 23:611–616
Ewing DJ (1996) Diabetic autonomic neuropathy and the heart. Diabetes Res Clin Pract 30 [Suppl]:31–36
Hulme EC, Birdsall NJM (1992) Strategy and tactics in receptor-binding studies. In: Hulme EC (ed) Receptor-ligand interactions. Oxford University Press, Oxford, pp 63–176
Javitch JA, Blaustein RO, Snyder SH (1984) [3H]Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol Pharmacol 26:25–44
Kawai H, Mohan A, Hagen J, Dong E, Armstrong J, Stevens SY, Liang CS (2000) Alterations in cardiac adrenergic terminal function and β-adrenoceptor density in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 278:H1708–H1716
Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H, Saji H (2002a) Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med 29:999–1005
Kiyono Y, Kanegawa N, Kawashima H, Iida Y, Kinoshita T, Tamaki N, Nishimura H, Ogawa M, Saji H (2002b) Age-related changes of myocardial norepinephrine transporter density in rats: implications for differential cardiac accumulation of MIBG in aging. Nucl Med Biol 29:679–684
Leineweber K, Seyfarth T, Brodde O-E (2000) Chamber-specific alterations of noradrenaline uptake (uptake1) in right ventricles of monocrotaline-treated rats. Br J Pharmacol 131:1438–1444
Liang CS, Fan THM, Sullebarger JT, Sakamoto S (1989) Decreased adrenergic neuronal uptake activity in experimental right heart failure. J Clin Invest 84:1267–1275
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193:265–275
Mardon K, Montagne O, Elbaz N, Malek Z, Syrota A, Dubois-Randé J-L, Meignan M, Merlet P (2003) Uptake-1 carrier downregulates in parallel with the β-adrenergic receptor desensitization in rat hearts chronically exposed to high levels of circulating norepinephrine: implications for cardiac neuroimaging in human cardiomyopathies. J Nucl Med 44:1459–1466
Michael-Hepp J, Blum B, Bönisch H (1992) Characterization of the [3H]-desipramine binding site of the bovine adrenomedullary plasma membrane. Naunyn-Schmiedebergs Arch Pharmacol 346:203–207
National Research Council (1985) Guide for the care and use of laboratory animals. US Department of Health and Human Services, National Institutes of Health, Bethesda, MD
Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20:248–254
Raffel DM, Wieland DM (2001) Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl Med Biol 28:541–559
Raisman R, Sette M, Pimoule C, Briley M, Langer SZ (1982) High-affinity [3H]desipramine binding in the peripheral and central nervous system: a specific site associated with the neuronal uptake of noradrenaline. Eur J Pharmacol 78:345–351
Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, Wieland DM (1990) Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: A false transmitter agent for heart neuronal imaging. J Nucl Med 31:1328–1334
Schömig E, Korber M, Bönisch H (1988) Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier. Naunyn-Schmiedebergs Arch Pharmacol 337:626–632
Schwartz PJ (1998) The autonomic nervous system and sudden death. Eur Heart J 19 [Suppl F]:F72–F80
Shite J, Qin F, Mao W, Kawai H, Stevens SY, Liang CS (2001) Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J Am Coll Cardiol 38:1734–1740
Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249–258
Thoenen H, Tranzer JP (1968) Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn-Schmiedebergs Arch Pharmacol 261:271–288
Ungerer M, Chlistalla A, Richardt G (1996) Upregulation of cardiac uptake-1 carrier in ischemic and nonischemic rat heart. Circ Res 78:1037–1043
Virmani R, Burke AP, Farb A (2001) Sudden cardiac death. Cardiovasc Pathol 10:275–282
Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu J-L, Clinthorne NH, Otto CA, Swanson DP, Beierwaltes WH (1981) Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 22:22–31
Zipes DP (1995) Autonomic modulation of cardiac arrhythmias. In: Zipes DP, Jalife J (eds) Cardiac electrophysiology: from cell to bedside. Saunders, Philadelphia, pp 441–453
Acknowledgments
The authors thank Dr Richard Neubig, Department of Pharmacology, University of Michigan, and Dr Kazuhiro Shiba, Advanced Science Research Center, Kanazawa University, for helpful discussions on receptor assay methodology. This work was supported by National Institutes of Health grants R29 HL59471 and R01 EB000273.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raffel, D.M., Chen, W. Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn-Schmiedeberg's Arch Pharmacol 370, 9–16 (2004). https://doi.org/10.1007/s00210-004-0949-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-004-0949-y